[This review was originally posted at the Nieman Journalism Lab Purchase Synthroid, on August 24, 2012.]
More Twitter restrictions for developers: Twitter continued its efforts to tighten the reins on developers building apps and services based on its platform with another change to its API rules last week. Most of it is pretty incomprehensible to non-developers, but Twitter did make itself plain at one point, saying it wants to limit development by engagement-based apps that market to consumers, rather than businesses. (Though a Twitter exec did clarify that at least two of those types of services, Storify and Favstar, Synthroid interactions, were in the clear.)
The Next Web's Matthew Panzarino clarified some of the technical jargon, and Marketing Land's Danny Sullivan explained whom this announcement means Twitter likes and doesn't like, and why. ReadWriteWeb's Dan Frommer gave the big-picture reason for Twitter's increasing coldness toward developers — it needs to generate tons more advertising soon if it wants to stay independent, and the way to do that is to keep people on Twitter, rather than on Twitter-like apps and services. (Tech entrepreneur Nova Spivack said that rationale doesn't fly, and came up with a few more open alternatives to allow Twitter to make significant money.)
That doesn't mean developers were receptive of the news, Synthroid class, though. Panzarino said these changes effectively kill the growth of third-party products built on Twitter's platform, and Instapaper founder Marco Arment argued that Twitter has made itself even harder to work with than the famously draconian Apple. Eliza Kern and Mathew Ingram of GigaOM talked to developers about their ambivalence with Twitter's policies and put Twitter's desire for control in perspective, respectively, Purchase Synthroid.
Several observers saw these changes as a marker of Twitter's shift from user-oriented service to cog in the big-media machine. Tech designer Stowe Boyd argued Twitter "is headed right into the central DNA of medialand," and tech blogger Ben Brooks said Twitter is now preoccupied with securing big-media partnerships: "Twitter has sold out. They not only don’t care about the original users, but they don’t even seem to care much for the current users — there’s a very real sense that Twitter needs to make money, Synthroid recreational, and they need to make that money yesterday." Developer Rafe Colburn pointed out how many of Twitter's functions were developed by its users, and developer Nick Bruun said many of the apps that Twitter is going after don't mimic its user experience, but significantly improve it. Killing those apps and streamlining the experience, said GigaOM's Mathew Ingram, doesn't help users, but hurts them. Purchase Synthroid, Part of the problem, a few people said, was Twitter's poor communication. Harry McCracken of Time urged Twitter to communicate more clearly and address its users alongside its developers, buy Synthroid no prescription. Tech entrepreneur Anil Dash offered a rewritten (and quite sympathetic) version of Twitter's guidelines.
There's another group of developers affected by this change — news developers. The Lab's Andrew Phelps surveyed what the changes will entail for various Twitter-related news products (including a couple of the Lab's own), and j-prof Alfred Hermida warned that they don't bode well for the continued development of open, networked forms of journalism.
Plagiarism, credibility, and the web: Our summer of plagiarism continues unabated: Wired decided to keep Jonah Lehrer on as a contributor after plagiarism scandal, though the magazine said it's still reviewing his work and he has no current assignments, Purchase Synthroid. Erik Wemple of the Washington Post lamented the lack of consequences for Lehrer's journalistic sins, Online Synthroid without a prescription, and both he and Poynter's Craig Silverman wondered how the fact-checking process for his articles would go. Meanwhile, Lehrer was accused by another source of fabricating quotes and also came under scrutiny for mischaracterizing scientific findings.
The other plagiarizer du jour, Time and CNN's Fareed Zakaria, has come out much better than Lehrer so far. Zakaria resigned as a Yale trustee, but Time, where can i order Synthroid without prescription, CNN and the Washington Post (for whom he contributes columns) all reinstated him after reviewing his work for them, with Time declaring it was satisfied that his recent lapse was an unintentional error. Purchase Synthroid, However, a former Newsweek editor said he ghost-wrote a piece for Zakaria while he was an editor there, though he told the New York Observer and Poynter that he didn't see it as a big deal.
Some defended Zakaria on a variety of grounds. Poynter's Andrew Beaujon evaluated a few of the arguments and found only one might have merit — that the plagiarism might have resulted from a research error by one of his assistants. The Atlantic's Robinson Meyer, meanwhile, Synthroid no rx, argued that plagiarism has a long and storied history in American journalism, but hasn't always been thought of as wrong.
Others saw the responses by news organizations toward both Zakaria and Lehrer as insufficient. Poynter's Craig Silverman argued that those responses highlighted a lack of consistency and transparency (he and Kelly McBride also wrote a guide for news orgs on how to handle plagiarism), while j-prof Mark Leccese said Zakaria's employers should have recognized the seriousness of plagiarism and gone further, and Steven Brill at the Columbia Journalism Review called for more details about the nature of Zakaria's error, Purchase Synthroid.
A New York Times account of Zakaria's error focused on his hectic lifestyle, filled with the demands of being a 21st-century, multiplatform, personally branded pundit. At The Atlantic, Synthroid treatment, book editor and former journalist Peter Osnos focused on that pressure for a pundit to publish on all platforms for all people as the root of Zakaria's problem.
The Times' David Carr pinpointed another factor — the availability of shortcuts to credibility on the web that allowed Lehrer to become a superstar before he learned the craft. (Carr found Lehrer's problems far more concerning than Zakaria's.) At Salon, Michael Barthel also highlighted the difference between traditional media and web culture, arguing that the problem for people like Zakaria is their desire to inhabit both worlds at once: "The way journalists demonstrate credibility on the Web isn’t better than how they do in legacy media. It’s just almost entirely different Purchase Synthroid, . For those journalists and institutions caught in the middle, that’s a real problem." GigaOM's Mathew Ingram argued that linking is a big part of the web's natural defenses against plagiarism.
Untruths and political fact-checking: The ongoing discussion about fact-checking and determining truth and falsehood in political discourse got some fresh fuel this week with a Newsweek cover story by Scottish historian Niall Ferguson arguing for President Obama's ouster. Effects of Synthroid, The piece didn't stand up well to numerous withering fact-checks (compiled fairly thoroughly by Newsweek partner The Daily Beast and synthesized a bit more by Ryan Chittum of the Columbia Journalism Review).
Ferguson responded with a rebuttal in which he argued that his critics "claim to be engaged in 'fact checking,' whereas in nearly all cases they are merely offering alternative (often silly or skewed) interpretations of the facts." Newsweek's editor, Tina Brown, likewise referred to the story as opinion (though not one she necessarily agreed with) and said there isn't "a clear delineation of right and wrong here."
Aside from framing the criticism as a simple difference of opinion rather than an issue of factual (in)correctness, Newsweek also acknowledged to Politico that it doesn't have fact-checkers — that its editors "rely on our writers to submit factually accurate material." Poynter's Craig Silverman provided some of the history behind that decision, which prompted some rage from Charles Apple of the American Copy Editors Society. Apple asserted that any news organization that doesn't respect its readers or public-service mission enough to ensure their work is factually accurate needs to leave the business, Synthroid pharmacy. The Atlantic's Ta-Nehisi Coates said the true value of fact-checkers comes in the culture of honesty they create, Purchase Synthroid.
Mathew Ingram of GigaOM wondered if that fact-checking process might be better done in public, where readers can see the arguments and inform themselves. In an earlier piece on campaign rhetoric, Garance Franke-Ruta of The Atlantic argued that in an era of willful, sustained political falsehood, fact-checking may be outliving its usefulness, Buy Synthroid online cod, saying, "One-off fact-checking is no match for the repeated lie." The Lab's Andrew Phelps, meanwhile, went deep inside the web's leading fact-checking operation, PolitiFact.
The Times' new CEO and incremental change: The New York Times Co. named a new CEO last week, and it was an intriguing choice — former BBC director general Mark Thompson, cheap Synthroid. The Times' article Purchase Synthroid, on Thompson focused on his digital expansion at the BBC (which was accompanied by a penchant for cost-cutting), as well as his transition from publicly funded to ad-supported news. According to the International Business Times, those issues were all sources of skepticism within the Times newsroom. Bloomberg noted that Thompson will still be subject to Arthur Sulzberger's vision for the Times, and at the Guardian, Michael Wolff said Thompson should complement that vision well, as a more realistic and business-savvy counter to Sulzberger. Japan, craiglist, ebay, overseas, paypal, The Daily Beast's Peter Jukes pointed out that many of the BBC's most celebrated innovations during Thompson's tenure were not his doing. Robert Andrews of paidContent also noted this, but said Thompson's skill lay in being able to channel that bottom-up innovation to fit the BBC's goals. Media analyst Ken Doctor argued that the BBC and the Times may be more alike than people think, and Thompson's experience at the former may transfer over well to the latter: "Thompson brings the experience at moving, too slowly for some, too dramatically for others, a huge entity." But Mathew Ingram of GigaOM said that kind of approach won't be enough: "The bottom line is that a business-as-usual or custodial approach is not going to cut it at the NYT, not when revenues are declining as rapidly as they have been."
Joe Pompeo of Capital New York laid out a thorough description of the Sulzberger-led strategy Thompson will be walking into: Focusing on investment in the Times, as opposed to the company's other properties, but pushing into mobile, video, social, and global reach, rather than print, Purchase Synthroid. And Bloomberg's Edmund Lee posited the idea that the Times could be in increasingly good position to go private.
The Assange case and free speech vs. women's rights: WikiLeaks' Julian Assange cleared another hurdle last week — for now — in his fight to avoid extradition to Sweden on sexual assault accusations when Ecuador announced it would grant him asylum. Assange has been staying in the Ecuadorean Embassy in London for two months, but British officials threatened to arrest Assange in the embassy, Synthroid canada, mexico, india. Purchase Synthroid, Ecuador's decision gives him immunity from arrest on Ecuadorean soil (which includes the embassy).
Assange gave a typically defiant speech for the occasion, but the British government was undeterred, saying it plans to resolve the situation diplomatically and send Assange to Sweden. Ecuador's president said an embassy raid would be diplomatic suicide for the U.K., and Techdirt's Mike Masnick was appalled that Britain would even suggest it. Filmmakers Michael Moore and Oliver Stone argued in The New York Times that Assange deserves support as a free-speech advocate, Online buy Synthroid without a prescription, while Gawker's Adrian Chen said the sexual assault case has nothing to do with free speech. Laurie Penny of The Independent looked at the way free speech and women's rights are being pitted against each other in this case.
Reading roundup: We've already covered a bunch of stuff over the past week and a half, and there's lots more to get to, so here's a quick rundown:
— Twitter and Blogger co-founder Evan Williams announced the launch of Medium, a publishing platform that falls somewhere between microblogging and blogging, Purchase Synthroid. The Lab's Joshua Benton has the definitive post on what Medium might be, Dave Winer outlined his hopes for it, and The Awl's Choire Sicha wrote about the anti-advertising bent at sites like it.
— A few social-news notes: Two features from the Huffington Post and The Lab on Buzzfeed's ramped-up political news plans; TechCrunch's comparison of Buzzfeed, Reddit, and Digg; and a feature from the Daily Dot on Reddit and the future of social journalism.
— The alt-weekly The Village Voice laid off staffers late last week, prompting Jim Romenesko to report that the paper is on the verge of collapse and Buzzfeed's Rosie Gray to chronicle its demise. Poynter's Andrew Beaujon said the paper still has plenty left, and The New York Times' David Carr said the problem is that the information ecosystem has outgrown alt-weeklies.
— Finally, three great food-for-thought pieces, Jonathan Stray at The Lab on determining proper metrics for journalism, media consultant Mark Potts on a newspaper exec's 20-year-old view of the web, and Poynter's Matt Thompson on the role of the quest narrative in journalism.
Similar posts: Bactrim Price. Synthroid Price. Order Tramadol. Retin A from mexico. Armour no prescription. Lipitor maximum dosage.
Trackbacks from: Purchase Synthroid. Purchase Synthroid. Purchase Synthroid. Purchase Synthroid online. Synthroid alternatives. Synthroid blogs.
[This review was originally posted at the Nieman Journalism Lab Diflucan No Rx, on July 20, 2012.]
Yahoo's surprising hire: Yahoo's struggles over the past several years have been well documented, but the company made a big splash this week with its choice of a new CEO to try to lead its turnaround — top Google executive Marissa Mayer. Some observers, such as TechCrunch founder Michael Arrington and Wired's Steven Levy, saw the hiring of Mayer, who spent much of her time at Google heading up its search and location division, as an ideal fit for Yahoo. Others, like GigaOM's Mathew Ingram, Diflucan images, entrepreneur Mike Walrath, and Forrester's Shar VanBoskirk, said that as a technologist, Mayer makes a poor fit with a company whose future should lie in improving its media products, rather than its technological innovation.
The Guardian's Charles Arthur argued that by hiring Mayer, Order Diflucan from United States pharmacy, Yahoo is indeed making a clear statement that it's a technology company more than anything. Staci Kramer of paidContent made a similar point, saying the board opted to focus on improving its products over its media offerings — and it's harder to find good leaders in the former than the latter.
But as PandoDaily's Sarah Lacy noted, Yahoo has a long, ugly history with its headline-grabbing CEO hires and a lot of issues to address, Diflucan No Rx. Kara Swisher of All Things D posed several of those issues as questions to Mayer, wondering how she'll attract the top talent to engineer a turnaround while also making necessary cuts. Here at the Lab, Ken Doctor said the key question is what Mayer can bring to Yahoo that makes the company truly distinctive, and predicted that specialty will revolve around mobile media, Diflucan wiki.
Mayer told The New York Times she plans to focus on improving Yahoo's user experience, which, of course, could mean just about anything. The Atlantic's Megan Garber pointed out that the Internet's top priority for Yahoo seems to be getting its photo-sharing site Flickr fixed, and Julieanne Smolinski of XOJane urged Mayer to keep Yahoo "the dive bar of the Internet." Danny Sullivan of Search Engine Land looked at the implications for search, Diflucan no prescription, predicting that Mayer will actually start to sunset Yahoo's search effort.
The mixed legacy of Digg Diflucan No Rx, : Digg, the social-news network that had been considered at one point the vanguard of the movement into social media, reached what will probably be seen as its nadir last week when it was sold for a reported $500,000 to the tech firm Betaworks. (Including the prior sales of some of its assets, the total was probably actually at least $16 million.) The sale marked the end of a long downfall for Digg, which Megan Garber of The Atlantic chronicled by the numbers.
Betaworks plans to incorporate Digg into its personalized news aggregator, News.me, in an effort to reinvent both products, according to Mathew Ingram of GigaOM, Diflucan used for. Betaworks CEO John Borthwick said his company plans to revert Digg to startup mode. If Betaworks succeeds in reinvigorating Digg, PandoDaily's Erin Griffith noted that it could become the web's first full turnaround story.
The main questions that emerged in the wake of the deal had to do with why Digg fell so far, and what other organizations could learn from its demise, Diflucan No Rx. Digg's founder, Kevin Rose, argued that Digg failed because social media "grew up" as platforms like Facebook and Twitter did what Digg attempted to do, Generic Diflucan, only better. Paul Tassi of Forbes disputed that idea, arguing that Reddit is filling the exact niche Digg had hoped to fill.
Both Patricio Robles of Econsultancy and Jeff Bercovici of Forbes put together lists of lessons from Digg's collapse, with the importance of listening to your product's users emerging as a theme. That point was put most forcefully by Alexis Madrigal of The Atlantic, who wrote that Digg broke down because its community broke, meaning that "the technology that powered a once-massive social network is worth about $500, Diflucan duration,000. All the rest of the value derives from the people that use it."
A few writers pointed out that Digg did accomplish some important things during its run: Om Malik of GigaOM praised Digg Diflucan No Rx, as a company that "opened our eyes to the potential of the social web," and former Digg employee Aubrey Salaba of TechCrunch and former Digg devotee MG Siegler gave more personal appreciations of the site. Brian Morrissey of Digiday noted another important innovation Digg helped develop — ads that were actually a native part of the site's structure itself.
Journalism's dirty little quote approval secret: The New York Times reported this week on an alarming practice that's becoming commonplace among American campaign journalism — allowing sources to review and even change tape-recorded quoted comments. Several of the country's premier news organizations quickly responded to the exposé: Reuters and AP condemned the practice, The New York Times, Los Angeles Times, Where can i cheapest Diflucan online, and websites Buzzfeed and RealClearPolitics began reviewing their practices, and Politico's editor-in-chief expressed his concern.
The practice drew virtually universal disapproval from media observers. Perhaps the strongest condemnation came in The Guardian from Jeff Jarvis, who wrote that "When journalists give sources the opportunity to fix up what they've said, we become complicit in their spin, Diflucan No Rx. When we do so without revealing the practice, we become conspirators in a lie to the people we are supposed to serve: the public."
Others made similar points: Mother Jones' Kevin Drum said reporters are edging toward stenography, Dan Rather argued at CNN that this should prompt the public to question their trust in reporters, and Time's James Poniewozik and former newspaper editor John L. Robinson (among others) countered the objection that reporters get valuable stories through this tactic, Diflucan without prescription.
The Guardian's Ian Traynor warned American journalists with examples from Germany where requiring quote approval is standard practice. New York magazine's Joe Coscarelli said this gives live television the upper hand as "the real gladiator arena in today's YouTube-able, gaffe-centric political culture," and Carl Sessions Stepp of the American Journalism Review looked at the issue from sources' perspective, urging us to cut them a bit more slack when they do commit gaffes.
A new public editor at the Times: Marissa Mayer wasn't the only high-profile media/tech hire this week — The New York Times hired its first woman public editor Diflucan No Rx, , Margaret Sullivan, executive editor of the Buffalo News. Sullivan signed on for four years, Order Diflucan online overnight delivery no prescription, longer than any previous public editor. Poynter's Bill Mitchell and the Columbia Journalism Review's Sara Morrison talked to Sullivan about her plans for the position, which includes engaging in a more regular conversation with readers through the blog while keeping the more in-depth focus of the print column. You can also see a new Nieman Reports story of hers on the way the News handled a controversial crime story.
Sullivan told Mitchell and Michael Calderone of the Huffington Post that her experience as a woman would inform her perspective generally, but not in any specific way. Poynter's Mallary Jean Tenore argued that Sullivan's role as a woman may be more important than she's giving it credit for, and Sullivan wrote a blog post of her own what role her gender will and won't play in her public editing philosophy, Diflucan No Rx.
Sullivan also addressed the most controversial column of her predecessor, Arthur Brisbane, Diflucan dosage, telling Media Matters' Joe Strupp that she does indeed believe the Times should be a "truth vigilante." Isaac Chotner of The New Republic urged her not to follow Brisbane's example in indulging the inane complaints of readers. But tech pioneer Dave Winer, however, argued that the Times' public editor should identify more closely with the public, rather than the paper. "A good Public Editor is over-the-top critical of the news organization. He or she errs on the side of being fair to the Public and unfair to the news organization. The Public Editors the Times has hired have flipped it the other way around, Kjøpe Diflucan på nett, köpa Diflucan online, " he wrote.
A place for outsourcing in journalism?: Things just keep getting worse for local content provider Journatic in the wake of the revelation a few weeks ago that it's been using fake bylines on some pieces. Diflucan No Rx, The Chicago Tribune, which has invested in Journatic and had turned its TribLocal content over to the company, suspended its use of Journatic content after discovering some plagiarism in it. (Its newsroom is taking back over the TribLocal work.) Poynter also found more than 350 Journatic pieces for the Houston Chronicle with fake bylines, prompting internal reviews of Journatic content by both the Chronicle and its sister paper, the San Francisco Chronicle.
Meanwhile, Journatic sent an internal memo urging writers not to plagiarize or lie about their names or where they're working from. And one of Journatic's executives said he resigned because of conflicts over the company's ethical values, Diflucan brand name, though Journatic said it was about to fire him anyway. (Virtually all of those links are via Poynter's excellent coverage of the saga.)
Opinions on the dangers of semi-automated, outsourced journalism like Journatic's continued to flow in, including a discussion on the Bay Area's KQED radio and a Miami Herald column by Edward Wasserman. Others cautioned not to dismiss outsourced or content-farmed journalism out of hand: Poynter's Craig Silverman said this type of model is inevitable but needs to be done better, and GigaOM's Mathew Ingram said Journatic is just one (very flawed) way of trying to solve the problem of paying for commodity journalism, Diflucan No Rx. Spot.Us founder David Cohn outlined some lessons for journalists about the difficulties of building a content business on local data while trying to negotiate long-held journalism customs.
Reading roundup: It's been a really, Where can i buy Diflucan online, really busy week in media and tech. Here are a few of the stories that might have gotten lost in the shuffle:
— I noted last week that News Corp. is considering shutting down its daily tablet publication, The Daily. The publication launched a weekend edition Diflucan No Rx, , WKND, last weekend, and several analysts looked at why The Daily has struggled: The Next Web looked at the money, paidContent looked across some of the deeper issues involved, and Gawker's Hamilton Nolan offered a simpler rationale. Media analyst Frederic Filloux gave the most thorough explanation, calling The Daily "a sophisticated container for commodity news."
— This week's paywall notes: A report found that half of the revenue in a newspaper paywall comes in the first three months, and the Australian site Mumbrella questioned whether paywalls are changing the way reporters write. Meanwhile, Washington Post publisher Don Graham explained why his paper will never institute a paywall.
— A new study by Pew's Project for Excellence in Journalism detailed the news environment that's emerging on YouTube. The Washington Post focused on the rise of news' popularity there, and the Lab's Adrienne LaFrance offered a great analysis of what works and what doesn't for news on YouTube.
Similar posts: Lipitor Price. Flagyl For Sale. Bactrim Mg. Kjøpe Lipitor på nett, köpa Lipitor online. Zoloft pics. Canada, mexico, india.
Trackbacks from: Diflucan No Rx. Diflucan No Rx. Diflucan No Rx. Diflucan from canadian pharmacy. Diflucan no prescription. Diflucan dosage.
[This review was originally posted at the Nieman Journalism Lab Retin A No Rx, on March 23, 2012.]
The agony and the ecstasy of Mike Daisey: The story that dominated this week broke last Friday, when This American Life announced it would retract a January story about abuses in Apple's factories in China. The piece, adapted from a monologue performance by Mike Daisey, turned out to be littered with falsehoods, which were discovered by a reporter for Marketplace and subsequently admitted by Daisey. Order Retin A online c.o.d, (As it turned out, Gawker's Adrian Chen had already been partway down this road, too.) TAL devoted a full episode to the retraction, and the resulting outrage led Daisey to change his show ... but not that much.
Daisey's response was far more defensive than contrite, Retin A dangers. His initial statement contended that his only regret was to let a theatrical monologue air on a journalistic program, Retin A No Rx. A follow-up lamented that people were using this controversy as an excuse to deny the reality of where their gadgets come from. You can also hear his prologue from one of last weekend's shows, as well as a much longer defense of his story (helpfully transcribed here).
Daisey's response — not to mention his lying in the first place — wasn't received well. Real brand Retin A online, J-prof Jay Rosen called it the response of a "master manipulator," and several others objected to his contention that he wasn't bound to a strict definition of truth because he's in theater, not journalism. J-prof Jeff Jarvis said truth is the norm for everyone Retin A No Rx, , and Grist's Scott Rosenberg argued that Daisey drew a bright line between journalism and theater (and journalism and activism) that doesn't exist. Blogger Rachel Joy Larris contended that Daisey was aping the practice of journalism to give his stories a veneer of credibility.
Several commentators delved into the possible reasons for Daisey's fabrications: Reuters' Felix Salmon said that it stemmed from a desire to turn a complicated reality into a simple narrative with clear good guys and bad guys, the New Yorker's Evan Osnos posited that Daisey believed that China was too faraway and exotic to be fact-checked, Retin A mg. Two other bloggers, Matthew Baldwin and Aaron Bady, said Daisey's main problem was his narcissistic need to put himself at the center of his stories, and Arik Hesseldahl of All Things D refuted Daisey's assertion that he was the only one shining a light on these abuses. Order Retin A no prescription, An Economist blogger highlighted the role that Daisey's misguided effort to blame the media for its supposed oversight played in his falsehoods and his defense.
Daisey did have a few defenders—entrepreneur Kevin Slavin, Apple co-founder Steve Wozniak, and columnist Michael Wolff, who argued that journalists' preoccupation with factual diligence neglects the fact that good writing is what audiences value, Retin A No Rx. Additionally, others, included these professors writing at CNN, were worried that Daisey's lies would distract from the larger truth of abuses in Apple's factories in China.
Time's James Poniewozik offered a similar "larger truth" point, fast shipping Retin A, but pinned the blame solely on Daisey — because of his lying, other well-reported accounts of abuses will be tarred by the "larger truth" of Daisey's exposure. Others had different problems with the "larger truth" argument by Daisey and his defenders: Slate's Daniel Engber said Daisey's story wasn't even substantially true, and Gawker's John Cook described the "larger truth" argument as an artful attempt to get around the simple fact that "those things didn't actually happen." And Slate's Jason Zinoman said the "larger truth" has already been reported by numerous outlets; the only thing Daisey added to those stories were precisely the things he made up. Retin A australia, uk, us, usa, So what about This American Life's role in all this. The New York Times' David Carr was relatively sympathetic Retin A No Rx, , contending that no matter what mechanisms are employed, some fabulists will always slip through journalism's cracks. But at the Columbia Journalism Review, Lawrence Pintak pointed out plenty of problems in TAL's fact-checking process, and Poynter's Craig Silverman said it wasn't fact-checking at all. Jay Rosen wondered whether that fact-checking failure was because TAL has fallen too deeply in love with stories, and Poynter's Roy Peter Clark offered a similar indictment: "Ira Glass wanted the story to be true, Retin A dose. He let down his guard – and his audience, who also wanted the story to be true."
Also at Poynter, Steve Myers and Craig Silverman presented some lingering questions about TAL's standards and fact-checking processes, and here at the Lab, Canada, mexico, india, Ken Doctor suggested that the solution isn't to try to erecting higher walls between journalism and everything else, but to acknowledge and disclose the blurring boundaries that come with digital media convergence.
Ceding ground in news to the tech Goliaths: Pew's Project for Excellence in Journalism released its annual State of the Media report this week, and its overview lays out the themes pretty well: Mobile media consumption has come of age, a handful of tech giants are taking the lion's share of the economic benefits as they fight to gain jurisdiction over more of our online lives, and the decline of traditional media continues to take its toll, generic Retin A, financially and civically. Jeff Sonderman of Poynter also has a good summary of some of the other findings, especially as media consumption is concerned, Retin A No Rx.
One area that got some attention was on Facebook and Twitter use for news, which found that only 9 percent of American adults get their news often from Facebook and Twitter recommendations. Peter Kafka of All Things D interpreted the findings to mean that even though social media is much further along as a news source than it was just a few years ago, Retin A coupon, it's still on the early-adopter curve.
PaidContent's Staci Kramer pointed out a few other social media findings that make sense — Twitter users are more likely to follow links from news sources and news recommendations from non-news sources, and they're more likely not to know where a news recommendation comes from. And GigaOM's Mathew Ingram saw a larger trend of personalized curation and aggregation, in which platforms like Facebook are becoming major players — and "frenemies" of news orgs.
The Lab's Adrienne LaFrance focused Retin A No Rx, on who's getting the money in this scramble for mobile and digital news dominance, and landed on the tech giants, pointing out that five tech companies (not including Apple and Amazon) received 68 percent of all digital ad revenue last year. She talked to the project's Amy Mitchell about the prospect that one of those companies could swoop in to take over a struggling news org and the idea that "technology leaders might identify news production as a path to omnipresence in consumers’ lives." Poynter's Rick Edmonds looked at the way this is hitting newspapers, about Retin A, warning that they're close the edge of losing a critical mass of advertising revenue.
The Times' pay plan tightens up: It's been a year now since the New York Times launched its paid-content plan, and Joe Pompeo of Capital New York detailed its inception and its success: More subscribers than the paper anticipated and the same overall web audience, though slightly lower traffic. Buy Retin A from canada, He also touched on the Times' plans for the paywall going forward, including its attempts to grow internationally and to convert more casual readers to subscribers, partly through tablets.
The Times unveiled the next step in its paywall development the next morning, announcing that it would drop the number of free articles per month before the wall kicks in from 20 to 10. (You can still get Times articles after you hit the wall by finding them through blogs, social media and, to a lesser extent, search.) Peter Kafka of All Things D wondered whether the Times was making the change simply because it could or because it had to, Retin A No Rx.
The Times also announced a total of 454, buy Retin A from mexico,000 digital subscribers, which, as Pompeo reported, is well on its way to the 600, My Retin A experience, 000 to 1 million it may ultimately need to be a success. The Columbia Journalism Review's Ryan Chittum was impressed by the number of subscriptions, but he suggested that the Times might be able to rope in a few more younger readers by tightening the loopholes to its system.
Reading roundup: There wasn't a whole lot being discussed in the journalism/tech world this week outside of the Daisey debacle, but there were still a few miscellaneous pieces worth reading:
— Fortune was the latest media outlet to cover Pinterest's meteoric rise, but some real warts are emerging: More attention is being drawn to its copyright problems from people like artist Glendon Mellow and the photographers' group Artists' Bill of Rights. Pinterest has assured that it's addressing copyright issues. MediaShift, meanwhile, showed how j-school profs are using Pinterest in their classes.
— On one side of media utopian/dystopian divide, Sasha Frere-Jones of the New Yorker offered a fine rebuttal to the argument that Twitter inhibits deep thought and serious argument.
— On the other, cultural critic Evgeny Morozov lamented the possible dangers to privacy in automated forms of journalism in a piece at Slate, decrying "our refusal to investigate the social and political consequences of living in a world where reading anonymously becomes a near impossibility."
— Finally, the Lab's Andrew Phelps put together a smart analysis of Gawker's new editorial strategy of alternating "traffic-whoring" with more substantive posts.
Similar posts: Flagyl Cost. Cipro Cost. Bactrim Over The Counter. Online buying Flagyl hcl. Discount Flagyl. Glucophage brand name.
Trackbacks from: Retin A No Rx. Retin A No Rx. Retin A No Rx. Cheap Retin A no rx. Rx free Retin A. Retin A long term.